Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal

More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from its

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 30 July →